GlassScriptPhysician profile
Richard A Funaro
NPI 1831269810
$3,909.55
in general payments reported to CMS, 2019-2025
26 companies · $561 in 2025
The $561 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $223 · 2020: $215 · 2021: $309 · 2022: $520 · 2023: $921 · 2024: $1,160 · 2025: $561.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,642.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,641.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $647.57 | 2024-2025 | Watchman Flx |
| Astrazeneca Pharmaceuticals LP | $483.54 | 2019-2025 | Farxiga |
| Lilly USA, LLC | $431.01 | 2019-2025 | Mounjaro, Zepbound |
| E.R. Squibb & Sons, L.L.C. | $341.71 | 2022-2025 | Eliquis, Camzyos |
| Merck Sharp & Dohme LLC | $324.70 | 2019-2023 | Verquvo |
| Pfizer INC. | $252.20 | 2023-2025 | |
| Medtronic, INC. | $246.57 | 2022-2023 | Linq II |
| Abbvie INC. | $190.74 | 2021-2022 | |
| Janssen Pharmaceuticals, INC | $180.23 | 2019-2024 | Xarelto |
| Novo Nordisk INC | $130.42 | 2020-2024 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $120.41 | 2021-2023 | Trelegy Ellipta |
| Novartis Pharmaceuticals Corporation | $105.09 | 2022-2023 | |
| Alnylam Pharmaceuticals INC. | $83.30 | 2024-2025 | Amvuttra |
| Heartflow, INC. | $69.25 | 2023-2025 | Ffrct |
| Kiniksa Pharmaceuticals, LTD. | $48.77 | 2023 | Arcalyst |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kiniksa Pharmaceuticals International, Plc | $41.48 | 2024 | Arcalyst |
| Boehringer Ingelheim Pharmaceuticals, INC. | $25.98 | 2022 | |
| Atricure, INC. | $25.97 | 2023 | |
| Amgen INC. | $23.98 | 2023 | Repatha |
| Sunovion Pharmaceuticals INC. | $22.65 | 2019 | |
| Xeris Pharmaceuticals, INC. | $21.30 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $20.97 | 2020 | |
| Linus Health, INC. | $20.12 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $18.14 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $17.25 | 2021 | |
| Abbott Laboratories | $16.20 | 2023 | Mitraclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Funaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.